144 related articles for article (PubMed ID: 38758900)
61. Combined hepatectomy and radiofrequency ablation versus TACE in improving survival of patients with unresectable BCLC stage B HCC.
Hou YF; Wei YG; Yang JY; Wen TF; Xu MQ; Yan LN; Li B
Hepatobiliary Pancreat Dis Int; 2016 Aug; 15(4):378-85. PubMed ID: 27498577
[TBL] [Abstract][Full Text] [Related]
62. 131I-Labeled-Metuximab Plus Transarterial Chemoembolization in Combination Therapy for Unresectable Hepatocellular Carcinoma: Results from a Multicenter Phase IV Clinical Study.
Ma J; Wang JH
Asian Pac J Cancer Prev; 2015; 16(17):7441-7. PubMed ID: 26625741
[TBL] [Abstract][Full Text] [Related]
63. A new ALBI-based model to predict survival after transarterial chemoembolization for BCLC stage B hepatocellular carcinoma.
Lee IC; Hung YW; Liu CA; Lee RC; Su CW; Huo TI; Li CP; Chao Y; Lin HC; Hou MC; Huang YH
Liver Int; 2019 Sep; 39(9):1704-1712. PubMed ID: 31319016
[TBL] [Abstract][Full Text] [Related]
64. Validation of the six-and-twelve criteria among patients with hepatocellular carcinoma and performance score 1 receiving transarterial chemoembolization.
Wang ZX; Li J; Wang EX; Xia DD; Bai W; Wang QH; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH
World J Gastroenterol; 2020 Apr; 26(15):1805-1819. PubMed ID: 32351295
[TBL] [Abstract][Full Text] [Related]
65. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
66. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation.
Ni JY; Fang ZT; Sun HL; An C; Huang ZM; Zhang TQ; Jiang XY; Chen YT; Xu LF; Huang JH
Eur Radiol; 2020 Apr; 30(4):2377-2390. PubMed ID: 31900694
[TBL] [Abstract][Full Text] [Related]
67. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Buijs M; Reyes DK; Pawlik TM; Blackford AL; Salem R; Messersmith WA; Weekes CD; Mulcahy M; Kamel IR; Geschwind JF
Cancer; 2013 Mar; 119(5):1042-9. PubMed ID: 23132335
[TBL] [Abstract][Full Text] [Related]
68. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
69. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
70. Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
Arizumi T; Minami T; Chishina H; Kono M; Takita M; Yada N; Hagiwara S; Minami Y; Ida H; Ueshima K; Kamata K; Minaga K; Komeda Y; Takenaka M; Sakurai T; Watanabe T; Nishida N; Kudo M
Dig Dis; 2017; 35(6):589-597. PubMed ID: 29040992
[TBL] [Abstract][Full Text] [Related]
71. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
[TBL] [Abstract][Full Text] [Related]
72. Barcelona clinic liver cancer stage B hepatocellular carcinoma: transarterial chemoembolization or hepatic resection?
Jianyong L; Lunan Y; Wentao W; Yong Z; Bo L; Tianfu W; Minqing X; Jiaying Y
Medicine (Baltimore); 2014 Nov; 93(26):e180. PubMed ID: 25474433
[TBL] [Abstract][Full Text] [Related]
73. A retrospective pilot study of transarterial chemoembolisation using camrelizumab-eluting Callisphere beads for unresectable hepatocellular carcinoma.
Shi X; Wang Y; Ren J; Han X; Bi Y
BMC Cancer; 2023 Nov; 23(1):1144. PubMed ID: 38001447
[TBL] [Abstract][Full Text] [Related]
74. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
[TBL] [Abstract][Full Text] [Related]
75. Transarterial chemoembolization for hepatocellular carcinoma: development and external validation of the Munich-TACE score.
Op den Winkel M; Nagel D; Op den Winkel P; Trojan J; Paprottka PM; Steib CJ; Schmidt L; Göller M; Stieber P; Göhring P; Herbst A; Rentsch M; De Toni EN; Göke B; Gerbes AL; Kolligs FT
Eur J Gastroenterol Hepatol; 2018 Jan; 30(1):44-53. PubMed ID: 29076939
[TBL] [Abstract][Full Text] [Related]
76. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization.
Ciria R; López-Cillero P; Gallardo AB; Cabrera J; Pleguezuelo M; Ayllón MD; Luque A; Zurera L; Espejo JJ; Rodríguez-Perálvarez M; Montero JL; de la Mata M; Briceño J
Eur J Surg Oncol; 2015 Sep; 41(9):1153-61. PubMed ID: 26118317
[TBL] [Abstract][Full Text] [Related]
77. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.
Reyes DK; Vossen JA; Kamel IR; Azad NS; Wahlin TA; Torbenson MS; Choti MA; Geschwind JF
Cancer J; 2009; 15(6):526-32. PubMed ID: 20010173
[TBL] [Abstract][Full Text] [Related]
78. Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Zhang K; Sun X; Xie F; Jian W; Li C
J Cancer Res Ther; 2018 Jan; 14(1):196-200. PubMed ID: 29516985
[TBL] [Abstract][Full Text] [Related]
79. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
80. Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Zhang ZH; Liu QX; Zhang W; Ma JQ; Wang JH; Luo JJ; Liu LX; Yan ZP
World J Gastroenterol; 2017 Nov; 23(43):7735-7745. PubMed ID: 29209114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]